MarketCap
Facebook
X
Telegram
Brickell Biotech EBITDA | BBI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.32 M | -21.5 M | -40.2 M | -21 M | -24.4 M | -3.45 M | -12.6 M | -8.06 M | -8.24 M | -15 M | -29.1 M | -21.1 M | -5.32 M | -28.4 M | -26 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.45 M | -40.2 M | -18 M |
Quarterly EBITDA Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.03 M | -2.34 M | -4.33 M | - | -6.06 M | -1.44 M | -9.4 M | - | -13.3 M | -11.6 M | -9 M | - | -4.34 M | -5.12 M | -4.1 M | -10.8 M | -6.03 M | -2.98 M | -5.24 M | -3.6 M | -3.93 M | -5.08 M | -6.46 M | - | -2.46 M | -2.88 M | -2.65 M | - | -1.74 M | -765 K | -2.23 M | - | 551 K | -2.2 M | -3.56 M | - | -3.07 M | -3.12 M | -3.02 M | - | -8.25 M | -8.82 M | -8.8 M | - | -6.3 M | -6.96 M | 353 K | - | 18.1 M | -7.29 M | -8.14 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.1 M | -13.3 M | -4.3 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Innate Pharma S.A.
IPHA
|
-54 M | $ 1.54 | 1.98 % | $ 138 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
-10.6 M | - | -1.19 % | $ 28.7 M |  USA |
 |
BioMarin Pharmaceutical
BMRN
|
489 M | $ 57.1 | -0.14 % | $ 11 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-6.93 M | $ 1.19 | -4.03 % | $ 6.51 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
-80.8 M | $ 11.24 | -2.01 % | $ 240 K | USA |
 |
SIGA Technologies
SIGA
|
24.3 M | $ 3.14 | -3.83 % | $ 225 M | USA |
 |
Milestone Pharmaceuticals
MIST
|
-62 M | $ 0.68 | -7.49 % | $ 72.2 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
78.8 M | $ 94.9 | -3.91 % | $ 7.04 B | USA |
 |
Lipocine
LPCN
|
-10.3 M | $ 1.59 | -7.85 % | $ 8.66 M | USA |
 |
PTC Therapeutics
PTCT
|
906 M | $ 64.12 | -1.4 % | $ 5.1 B | USA |
 |
Seres Therapeutics
MCRB
|
-89.8 M | $ 1.55 | -8.75 % | $ 13.7 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
-299 M | $ 432.48 | -0.07 % | $ 9.7 B | USA |
 |
CEL-SCI Corporation
CVM
|
-22.8 M | $ 1.41 | 4.07 % | $ 11.3 M | USA |
 |
Inventiva S.A.
IVA
|
-97.6 M | $ 3.95 | 2.73 % | $ 236 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
-93.4 M | $ 9.62 | 1.37 % | $ 774 M | USA |
 |
Processa Pharmaceuticals
PCSA
|
-14 M | $ 1.86 | -4.62 % | $ 2.44 M | USA |
 |
Eton Pharmaceuticals
ETON
|
3.2 M | $ 67.5 | 4.9 % | $ 1.82 B | USA |
 |
IDEAYA Biosciences
IDYA
|
-157 M | $ 31.72 | -0.97 % | $ 2.81 B | USA |
 |
Protalix BioTherapeutics
PLX
|
-4.04 M | $ 2.86 | 11.28 % | $ 225 M |  Israel |
 |
Lantern Pharma
LTRN
|
-18 M | $ 0.47 | -22.86 % | $ 5.12 M | USA |
 |
Foghorn Therapeutics
FHTX
|
-83.1 M | $ 1.89 | -7.35 % | $ 119 M | USA |
 |
Ocugen
OCGN
|
-60.5 M | $ 0.95 | -2.45 % | $ 297 M | USA |
 |
Oncolytics Biotech
ONCY
|
-35 M | $ 0.38 | -5.64 % | $ 36.4 M | Canada |
 |
Minerva Neurosciences
NERV
|
-15.1 M | $ 2.47 | -6.08 % | $ 20.9 M | USA |
 |
Kamada Ltd.
KMDA
|
26.2 M | $ 8.09 | 4.93 % | $ 466 M | Israel |
 |
Neurocrine Biosciences
NBIX
|
645 M | $ 169.08 | 0.13 % | $ 16.8 B | USA |
 |
Nanobiotix S.A.
NBTX
|
-10.8 M | $ 32.8 | 2.4 % | $ 1.57 T | France |
 |
Mereo BioPharma Group plc
MREO
|
-43.6 M | $ 0.3 | 1.66 % | $ 239 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
-192 M | $ 7.86 | -2.31 % | $ 1.13 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
-48.3 M | $ 1.84 | 0.82 % | $ 668 M | USA |
 |
Moleculin Biotech
MBRX
|
-25 M | $ 8.01 | -7.51 % | $ 9.49 M | USA |
 |
Nurix Therapeutics
NRIX
|
-277 M | $ 15.89 | -1.58 % | $ 1.38 B | USA |
 |
Nkarta
NKTX
|
-113 M | $ 1.36 | -14.78 % | $ 101 M | USA |
 |
MacroGenics
MGNX
|
-65.7 M | $ 2.42 | 3.42 % | $ 153 M | USA |
 |
Protagonist Therapeutics
PTGX
|
-157 M | $ 136.18 | 0.2 % | $ 8.66 B | USA |
|
Nuvation Bio
NUVB
|
-211 M | $ 4.22 | -3.1 % | $ 1.44 B | USA |
 |
Novo Nordisk A/S
NVO
|
150 B | $ 40.6 | -1.88 % | $ 180 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
-12.9 M | $ 0.95 | -3.87 % | $ 14.5 M | USA |
 |
NextCure
NXTC
|
-15.1 M | $ 5.97 | -4.78 % | $ 17 M | USA |
 |
Rocket Pharmaceuticals
RCKT
|
-223 M | $ 2.46 | -2.96 % | $ 273 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
-86.1 M | $ 1.22 | -2.8 % | $ 64.1 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
-178 M | $ 7.29 | -1.02 % | $ 634 M | USA |
 |
Kymera Therapeutics
KYMR
|
-341 M | $ 136.45 | -1.74 % | $ 11.5 B | USA |
 |
Oragenics
OGEN
|
-9.36 M | $ 0.35 | -1.47 % | $ 755 K | USA |
 |
Ovid Therapeutics
OVID
|
-42.2 M | $ 2.8 | -1.75 % | $ 365 M | USA |
 |
Passage Bio
PASG
|
-8.12 M | $ 3.81 | 11.08 % | $ 12.2 M | USA |
 |
Vaxcyte
PCVX
|
-907 M | $ 66.44 | -1.61 % | $ 9.04 B | USA |
 |
Relay Therapeutics
RLAY
|
-299 M | $ 19.81 | -2.87 % | $ 3.4 B | USA |
 |
Precigen
PGEN
|
-107 M | $ 4.51 | -4.76 % | $ 1.41 B | USA |
 |
Avidity Biosciences
RNA
|
-742 M | $ 8.23 | -1.79 % | $ 1.13 B | USA |